<p>In this episode of #ThroughTheGenes, we delve into the transformative role of fetal hemoglobin in treating sickle cell disease. Join hosts - Wunmi Bakare and Christelle Salomon - as they explore groundbreaking gene therapy advancements with Dr. Matt Porteous, Co-founder of Kamau Therapeutics. </p><p>Discover how genome editing techniques are being used to reactivate fetal hemoglobin, offering new hope for patients by reducing the severity of sickle cell symptoms. We explore the FDA-approved therapies, Lyfgenia and Casgevy, and discuss the transformative potential these treatments hold. Discover the science behind these therapies, the journey from concept to approval, and the impact on patients' lives. Tune in to learn how gene therapy is reshaping the future for those living with sickle cell disease.</p>
